A new form of brain stimulation that requires no surgery is offering fresh hope to people living with Parkinson’s disease. Researchers say the technique, called transcranial temporal interference stimulation, or TIs, may be able to improve movement problems by stimulating deep regions of the brain from outside the skull. Early results suggest that the treatment could someday become an alternative or companion to traditional deep brain stimulation surgery.
Parkinson’s disease affects millions of people worldwide and causes symptoms such as tremors, stiffness, slowed movement, balance problems, and difficulty walking. One of the most effective treatments for advanced Parkinson’s has been deep brain stimulation, commonly called DBS. In DBS, surgeons implant electrodes deep inside the brain to send electrical pulses to regions involved in motor control. While effective, the procedure is invasive, expensive, and only used in a small percentage of patients because it requires brain surgery. Researchers noted that DBS is currently used in less than 3% of Parkinson’s patients globally.
The new study focused on whether similar benefits could be achieved without surgery. Scientists from Shanghai University of Sport and collaborating institutions in China conducted a pilot study using TIs, a technique that delivers overlapping high-frequency electrical currents through electrodes placed on the scalp. These currents intersect deep inside the brain, creating a lower-frequency electrical field capable of stimulating targeted brain regions without affecting as much of the surrounding tissue.
The researchers specifically targeted the subthalamic nucleus, often called the STN. This area of the brain is considered one of the most important targets for traditional deep brain stimulation because it plays a major role in motor control. The research team believed that if they could safely stimulate this region without surgery, patients might gain some of the same benefits seen with implanted DBS systems.
The study was published in the journal eBioMedicine and involved 30 people with early-to-mid-stage Parkinson’s disease. Participants were between Hoehn and Yahr stages 1.5 and 3, meaning they had noticeable symptoms but were still generally able to walk independently. The average age of participants was nearly 70 years old.
Researchers designed the study carefully to reduce bias. It was randomized, double blind, sham controlled, and crossover in design. That means participants received both the real stimulation and a fake treatment at different times, but neither the patients nor most of the researchers knew which session was real during testing. The order was randomized so expectations would not influence the results.
Each participant underwent MRI brain scans so researchers could customize the placement of the electrodes based on the person’s unique brain anatomy. This individualized approach was considered one of the most important features of the study because the researchers believed it could improve precision and treatment effectiveness. Researcher Brad Manor of Hebrew SeniorLife in Boston said, “One of the most promising aspects of this work is the ability to individualize stimulation based on each patient’s own brain anatomy. That level of precision could become increasingly important as we learn how to tailor neuromodulation therapies to different Parkinson’s symptoms and different patients.”
During the treatment sessions, participants received a single 20-minute stimulation session while off their Parkinson’s medications. Researchers then measured motor symptoms immediately after treatment, as well as 30 minutes and 60 minutes later, using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part III, commonly known as MDS-UPDRS-III.
The results were striking for an early-stage study. About 70% of participants experienced clinically meaningful improvement after receiving the real TIs treatment. By comparison, only about 15% improved after the sham treatment. Researchers reported a statistically significant difference between the two conditions, with a risk difference of 56.3% and a P value of less than 0.001.
The improvements were especially noticeable in tremor and bradykinesia, the slowness of movement commonly associated with Parkinson’s disease. Patients also showed measurable improvements in overall motor scores. Compared with sham treatment, TIs improved MDS-UPDRS-III total scores by an average of 4.18 points immediately after stimulation, 6.83 points after 30 minutes, and 6.12 points after 60 minutes. All of these differences were statistically significant.
Rigidity and balance symptoms improved less consistently, but researchers still considered the overall findings encouraging. The team emphasized that even short-term symptom relief from a single session suggests that deeper therapeutic effects could emerge with repeated treatments over time.
Safety was another major focus of the research. No serious adverse events occurred during the study. Most side effects were mild and temporary, such as tingling, warmth, itching, or slight pressure sensations beneath the electrodes. Importantly, the rate of side effects was similar between the real stimulation and the sham treatment, suggesting that the therapy was generally well tolerated.
Dr. Alvaro Pascual-Leone, medical director of the Deanna and Sidney Wolk Center for Memory Health at Hebrew SeniorLife in Boston, described the significance of the technology by saying, “TIs represents a fundamentally different approach to non-invasive neuromodulation, one that can reach deep brain targets without surgery.”
Researchers believe the technology could eventually change how Parkinson’s disease is treated. Instead of waiting until symptoms become severe enough to justify brain surgery, doctors may one day use noninvasive stimulation earlier in the disease process. Manor said, “A noninvasive technique like TIs could someday provide a valuable new option either before surgery is considered or alongside existing therapies.”
Still, the researchers cautioned that this was only a pilot study. The treatment effects were short term, and the study involved just 30 participants at a single research center in China. Larger studies will be needed to determine how long the benefits last, whether repeated sessions produce stronger or more durable improvements, and which patients are most likely to respond. Researchers also want to better understand exactly how the stimulation changes brain activity.
Even with those limitations, many scientists see this work as an important step forward. The idea that doctors may someday deliver deep brain stimulation without drilling into the skull could represent a major shift in neurological treatment. For people with Parkinson’s disease, especially those hesitant or unable to undergo surgery, that possibility may be one of the most exciting developments in years.
